Vivian W. Pinn, MD, was the inaugural full-time director of the Office of Research on Women’s Health at the National Institutes of Health (NIH) from 1991 and Associate Director of NIH for Women’s Health Research from 1994 until her retirement in 2011. Under her leadership, this new office led the implementation of NIH research inclusion policies, developed the first ever, and several later, national strategic plans for women’s health research and established many new research funding initiatives and career development programs, including interdisciplinary initiatives, in collaboration with NIH Institutes and Centers.  During that time, she also established and co-chaired the NIH Committee on Women in Biomedical Careers with the NIH Director.  She has since been named as a Senior Scientist Emerita at the NIH Fogarty International Center.  She has presented her perceptions of women’s health and sex/gender research, health disparities, as well as challenges in biomedical careers to national and international audiences and has over 200 scientific publications and book chapters.

She came to the NIH from Howard University College of Medicine, where she had been Professor and Chair of the Department of Pathology since 1982, the 3rd woman in the US to hold such an appointment. Dr. Pinn also previously held teaching appointments in Pathology at Harvard Medical School and Tufts University where she was also Assistant Dean for Student Affairs.  A special tribute by Senator Olympia Snowe on Dr. Pinn’s retirement was published in the Congressional Record in November 2011 commending her contributions during her NIH tenure. The Association of American Medical Colleges awarded her a Special Recognition Award for exceptional leadership over a forty-year career. 

She has received numerous honors and recognitions. She is a fellow of the American Academy of Arts and Sciences and was elected to the National Academy of Medicine (IOM) in 1995. A graduate and Alumna Achievement Award recipient as well as former Trustee of Wellesley College, she earned her M.D. in 1967 from the University of Virginia School of Medicine, the only woman and only minority in her class.  She completed her post-graduate training in Pathology at the Massachusetts General Hospital of Harvard University before joining the faculty of Tufts. 

A native of Lynchburg, Virginia, educated in segregated public schools, Dr. Pinn has received 15 Honorary Degrees of Science, Law and Medicine.  The University of Virginia School of Medicine has named one of its four advisory medical student colleges as ‘The Pinn College’ in her honor. Tufts University School of Medicine in 2011 announced the ‘The Vivian W. Pinn Office of Student Affairs’, named for her at the time her former medical students dedicated a scholarship in her name.  She has held leadership positions in many professional organizations, including that as the 88th President of the National Medical Association (NMA) and is currently Chair of the NMA Past Presidents Council. Dr. Pinn serves on the Board of Trustees/Advisors of Thomas Jefferson University and Tufts University School of Medicine. She was elected to Modern Healthcare’s Hall of Fame, the first African American woman to be so honored and is also a recipient of the New York Academy of Medicine Medal for Distinguished Contributions in Health Policy.

Among other recent honors, she received a special Lifetime Achievement Award from the Institute for Women’s Health and Leadership of Drexel University in 2017, and she also served as the 2017-2018 Leader-in-Residence at the Jepson School of Leadership Studies of the University of Richmond.  Lectures in women’s health named for her have been established at the National Institutes of Health, the National Women’s Health Congress, and the National Medical Association.  

One of her greatest honors has been the announcement by the University of Virginia in the fall of 2016 that the medical research and education building was renamed for her as “Pinn Hall.”   And in December 2016, the UVA medical school also announced the inaugural Pinn Scholars program to support and recognize mid-level faculty in efforts to take their research in novel directions.  Her oral history is included in the National Library of Medicine’s exhibit on women physicians, ‘Changing the Face of Medicine’; in the University of Virginia’s project ‘Explorations in Black Leadership’ conducted by Julian Bond; and, in The HistoryMakers collection which is now housed in the Library of Congress.  

Headshot - Sachin Jain.jpg





Sachin H. Jain, MD, MBA is President of CareMore Health. He is also consulting professor of medicine at the Stanford University School of Medicine and a contributor at Forbes. Dr. Jain was previously CareMore’s Chief Medical Officer and Chief Operating Officer. Prior to joining CareMore, Dr. Jain was Chief Medical Information & Innovation Officer at Merck & Co. He also served as an attending physician at the Boston VA-Boston Medical Center and a member of faculties at Harvard Medical School and Harvard Business School. From 2009-2011, Dr. Jain worked in the Obama Administration, where he was senior advisor to Donald Berwick when he led the Centers for Medicare & Medicaid Services. Dr. Jain was the first deputy director for policy and programs at the Center for Medicare and Medicaid Innovation. He also served as special assistant to David Blumenthal when he was the National Coordinator for Health Information Technology.


Dr. Jain graduated magna cum laude from Harvard College with a BA in government and continued on to earn his MD from Harvard Medical School and MBA from Harvard Business School. He trained in medicine at the Brigham and Women's Medicine, earned his board certification from the ABIM, and continues to practice medicine at CareMore. He is co-founder and co-editor-in-chief of the Elsevier journal Healthcare: The Journal of Delivery Science & Innovation. He has published over 100 peer-reviewed articles and in journals such as the New England Journal, JAMA, Health Affairs, and the Harvard Business Review blogs and was an editor of the book, The Soul of a Doctor (Algonquin Press). Dr. Jain was elected to the National Academy of Social Insurance in 2010.



President, BlueCross BlueShield Institute

SVP and CMO, BlueCross BlueShield Association

Trent Haywood, MD, JD, is senior vice president and chief medical officer for the Blue Cross Blue Shield Association (BCBSA), a national federation of 36 independent, community-based and locally operated Blue Cross and Blue Shield (BCBS) companies. The BCBS System is the nation's largest health insurer covering one-in-three of all Americans.

As the Association’s chief medical officer, Haywood supports the innovation of BCBS companies in communities around the country as they improve the choices of healthcare quality and patient safety for their members. He is responsible for the Office of Clinical Affairs, which includes the Center for Clinical Effectiveness, Center for Clinical Practices and the Center for Clinical Value. Collectively, the Office of Clinical Affairs supports opportunities between BCBS companies and stakeholders to improve the choices of affordable, high quality healthcare provided to members.

Haywood also serves as president of the BCBS Institute, an independent licensee of BCBSA and a first-of-its-kind benefit corporation established to address social determinants of health through technology and strategic collaborations. The Institute extends the traditional healthcare service delivery model into the community to enhance the capacity for health outcomes.

In addition, Haywood oversees the National Council of Physician Executives, which consists of chief medical officers and chief pharmacy executives that guide the clinical direction across BCBS companies. He provides clinical leadership for the 5.4 million-member Federal Employee Program and clinical guidance to Blue Health Intelligence, an independent licensee of the BCBSA. In 2018, Haywood was appointed by the Comptroller General of the U.S. to the governing board of the Patient-Centered Outcomes Research Institute, established to investigate the relative effectiveness of various medical treatments.

Before joining BCBSA, Haywood served as senior vice president and chief medical officer for VHA, Inc., where he developed best practices to drive quality, stimulate clinical innovation, and support pay-for-performance, and prepared for consumer-driven healthcare. Prior to joining VHA, he was deputy chief medical officer for the Centers for Medicare and Medicaid Services, where he led agency priorities including quality public reporting and value-based payment innovations.

Haywood received a bachelor’s degree from the University of Notre Dame and a medical degree from the University of Illinois in Chicago. He completed his internal medicine residency at Loyola University. Haywood also holds a law degree from Northwestern University School of Law.



President, Verily Life Sciences

Vivian S. Lee, MD, PhD, MBA is President of Health Platforms, Verily Life Sciences, an Alphabet company whose mission is to apply digital solutions that enable people enjoy healthier lives. A passionate champion of improving health in the U.S. and worldwide, she works closely with Verily’s clinical and engineering teams to develop products and platforms that support the successful transformation of health systems to value and advance the co-production of health with patients, their caregivers, and communities. A radiologist and healthcare executive, Lee also serves as a senior fellow at the Institute for Healthcare Improvement and is authoring a book about improving the American healthcare system.

For six years, Lee led the University of Utah Health as Dean, SVP and CEO of the $3.5B integrated health system, academic campus, and health plan. The system was recognized for its health care innovations that enabled higher quality at lower costs (JAMA & editorial, NYT) and with higher patient satisfaction (NYT, HBR, NEJM), and in 2016, was ranked first among university hospitals in quality and safety (Vizient).

 Elected to the National Academy of Medicine, and with ~200 peer-reviewed publications, Lee is an MR radiologist whose NIH-funded laboratory has developed novel methods for measuring kidney function and vascular disease with MRI. Also recognized for her leadership in transforming health care, Lee serves on the Defense Health Board of the Department of Defense, the Journal Oversight Committee for JAMA, the Board of Directors of the Commonwealth Fund, and the Scientific Advisory Boards for Massachusetts General Hospital and University of Pittsburgh School of Medicine. She is also a director on the board of Zions Bancorporation, a publicly traded company and also serves on the board of the American Association of Rhodes Scholars.

Dr. Lee is a magna cum laude graduate of Harvard, received a D.Phil in medical engineering from Oxford University as a Rhodes Scholar, earned her M.D. with honors from Harvard Medical School, and was valedictorian of her EMBA program at NYU’s Stern School of Business.



Founder, executive chairman, ceo, Butterfly Network

Jonathan Rothberg, MD, is a scientist and entrepreneur who was awarded the National Medal of Technology and Innovation, the nation’s highest honor for technological achievement, by president Obama for inventing and commercializing high-speed DNA sequencing. He is the founder of multiple life science and medical device companies including CuraGen, 454 Life Sciences, Ion Torrent, RainDance Technologies, Hyperfine Research, Quantum-Si, Lam Therapeutics, and Butterfly Network.

The idea for massively parallel (“Next-gen”) DNA sequencing came to Rothberg when his infant son was rushed into intensive care, helping him realize the critical importance of genomics to human health. With 454 Life Sciences, Rothberg brought to market the first new way to sequence genomes since Sanger and Gilbert won the Nobel Prize for their method in 1980. The New England Journal described Rothberg’s innovation as "The New Age of Molecular Diagnostics", and Science magazine called it one of the top 10 breakthroughs of 2008. With 454’s technology, Rothberg sequenced the first individual human genome (James Watson’s Genome, Nature cover), and with Svante Paabo he initiated the first large-scale effort to sequence ancient DNA (The Neanderthal Genome Project). Under his leadership, 454 undertook the first deep sequencing of a cancer, helped understand the mystery behind the disappearance of the honey bee, uncovered a new virus killing transplant patients, and elucidated the extent of human genomic variation—work recognized by Science magazine as the breakthrough of the year in 2007. Rothberg went on to invent semiconductor chip-based sequencing, with which he sequenced the genome of Gordon Moore (Moore’s Law, Nature cover), paving the way for the $1,000 Genome. His contributions to the field of sequencing include the first non-bacterial cloning method (cloning by limited dilution) and the first massively parallel DNA sequencing method (parallel sequencing by synthesis on a single substrate), concepts that have formed the basis for all subsequent next generation sequencing technologies.

Most recently, with Butterfly Network, Rothberg developed the first ultrasound instrument built entirely on a semiconductor chip, giving it greater imaging flexibility than any device on the market. Butterfly’s device received the widest FDA clearance ever given to an ultrasound probe, making it the world’s first handheld whole-body scanner at a cost 50-fold less than existing devices, launching an era of democratized medical imaging.

Rothberg was born in 1963 in New Haven, Connecticut. He earned a B.S. in chemical engineering from Carnegie Mellon and an M.S., M.Phil, and Ph.D. in biology from Yale. He is the first person to be named a World Economic Forum's Technology Pioneer four separate times, is an Ernst and Young Entrepreneur of the Year, is the recipient of The Wall Street Journal's First Gold Medal for Innovation, Nature Methods First Method of the Year Award, The Irvington Institute's Corporate Leadership Award in Science, the Connecticut Medal of Technology, the DGKL Biochemical Analysis Prize, and an Honorary Doctorate of Science from Mount Sinai. Rothberg is a member of the National Academy of Engineering, the Connecticut Academy of Science and Engineering, is a trustee of Carnegie Mellon, and an Adjunct Professor of Genetics at the Yale.

Headshot - Robert Galvin[1].jpg


Chief Executive Officer, Equity Healthcare

Operating Partner, Blackstone

Dr. Robert Galvin is the Chief Executive Officer of Equity Healthcare and an Operating Partner at Blackstone. Equity Healthcare (EH) oversees the management of healthcare for firms owned by private equity companies. EH encompasses 50+ companies with health care spending of $2 billion annually. EH is a wholly owned subsidiary of Blackstone, where Dr. Galvin is an Operating Partner. Before joining Blackstone, Dr. Galvin was Executive Director of Health Services and Chief Medical Officer for General Electric (GE) for fifteen years.

Dr. Galvin is a nationally recognized leader in the areas of employer-sponsored insurance, quality measurement and payment reform. His work has been published in the Harvard Business Review, New England Journal of Medicine, JAMA and Health Affairs and he was a co-founder of the Leapfrog Group and founder of two other groups, Bridges to Excellence/PROMETHEUS and Catalyze Payment Reform (CPR), all innovative non-profits which have helped define value-based purchasing.

Dr. Galvin is a member of the National Academy of Medicine and is Chairman of the Board of CPR.  He also serves on the boards of two for-profit companies, Team Health and Real Endpoints. He has received awards for his work from the National Business Group on Health, Healthcare Financial Management Association, and National Coalition for Cancer Survivorship. He is Professor Adjunct of Medicine and Health Policy at Yale and a fellow of the American College of Physicians.